trabectedin in ASPS, 6 patients study from Germany

[Olga]

Efficacy of trabectedin in patients with advanced or metastatic alveolar soft-part sarcoma.
https://www.ncbi.nlm.nih.gov/pubmed/22868503
The results are interesting.
In 6 patients with documented disease progression, disease stabilization was reached with trabectedin; only 1 patient experienced progressive disease. The mPFS and OS were 7 months and 21 months, respectively, since the start of trabectedin treatment. Overall, no severe Common Toxicity Criteria (CTC) grade 3 or 4 toxicity was observed.